OTCMKTS:SNYNF - Sanofi Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$101.35
+0.30 (1.20%)

This chart shows the closing price for SNYNF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sanofi Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNYNF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNYNF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $101.35.

This chart shows the closing price for SNYNF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Sanofi. This rating has held steady since April 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/26/2020JPMorgan Chase & Co.Reiterated RatingBuy
5/7/2020UBS GroupReiterated RatingBuy
4/27/2020Credit Suisse GroupReiterated RatingBuy
4/24/2020UBS GroupReiterated RatingBuy
4/9/2020JPMorgan Chase & Co.Reiterated RatingBuy
2/19/2020Kepler Capital MarketsReiterated RatingBuy
7/10/2019Jefferies Financial GroupReiterated RatingBuy$95.00
(Data available from 7/28/2016 forward)
Sanofi logo
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Read More

Today's Range

Now: $101.35
Low: $101.35
High: $101.35

50 Day Range

MA: $105.30
Low: $100.43
High: $109.40

52 Week Range

Now: $101.35
Low: $88.75
High: $112.65

Volume

33 shs

Average Volume

9,761 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sanofi?

The following Wall Street sell-side analysts have issued reports on Sanofi in the last year:
View the latest analyst ratings for SNYNF.

What is the current price target for Sanofi?

0 Wall Street analysts have set twelve-month price targets for Sanofi in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sanofi in the next year.
View the latest price targets for SNYNF.

What is the current consensus analyst rating for Sanofi?

Sanofi currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNYNF.

What other companies compete with Sanofi?

How do I contact Sanofi's investor relations team?

The company's listed phone number is 33 1 53 77 40 00. The official website for Sanofi is www.sanofi.com.